liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Caveats in studies of the physiological role of polyphosphates in coagulation
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Department of Clinical Chemistry.
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Medicine and Health Sciences.ORCID iD: 0000-0002-1920-3962
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Department of Clinical Chemistry.
2016 (English)In: Biochemical Society Transactions, ISSN 0300-5127, E-ISSN 1470-8752, Vol. 44, 35-39 p.Article in journal (Refereed) PublishedText
Abstract [en]

Platelet-derived polyphosphates (polyP), stored in dense granule and released upon platelet activation, have been claimed to enhance thrombin activation of coagulation factor XI (FXI) and to activate FXII directly. The latter claim is controversial and principal results leading to these conclusions are probably influenced by methodological problems. It is important to consider that low-grade contact activation is initiated by all surfaces and is greatly amplified by the presence of phospholipids simulating the procoagulant membranes of activated platelets. Thus, proper use of inhibitors of the contact pathway and a careful choice of materials for plates and tubes is important to avoid artefacts. The use of phosphatases used to degrade polyP has an important drawback as it also degrades the secondary activators ADP and ATP, which are released from activated platelets. In addition, the use of positively charged inhibitors, such as polymyxin B, to inhibit polyP in platelet-rich plasma and blood is problematic, as polymyxin B also slows coagulation in the absence of polyP. In conclusion we hope awareness of the above caveats may improve research on the physiological roles of polyP in coagulation. © 2016 Authors; published by Portland Press Limited.

Place, publisher, year, edition, pages
Portland Press Ltd , 2016. Vol. 44, 35-39 p.
Keyword [en]
Blood; Coagulation; Contact activation; Phosphatase; Platelets; Polyphosphate
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-126155DOI: 10.1042/BST20150220PubMedID: 26862185ScopusID: 2-s2.0-84957871941OAI: oai:DiVA.org:liu-126155DiVA: diva2:912102
Note

Funding Agencies|20140410, Hjärt-Lungfonden; K2013-65X-15060-10-3, Hjärt-Lungfonden

Available from: 2016-03-15 Created: 2016-03-15 Last updated: 2016-05-27

Open Access in DiVA

The full text will be freely available from 2017-02-09 10:29
Available from 2017-02-09 10:29

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Lindahl, TomasRamström, SofiaBoknäs, NiklasFaxälv, Lars
By organisation
Division of Microbiology and Molecular MedicineFaculty of Medicine and Health SciencesDepartment of Clinical Chemistry
In the same journal
Biochemical Society Transactions
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 462 hits
ReferencesLink to record
Permanent link

Direct link